FDA, Biogen continue to face blowback after Alzhemer’s drug approval
More than a month has passed since the U.S. Food and Drug Administration (FDA) approved the first Alzheimer’s drug, Aduhelm, in more than 20 years, but criticisms of the approval and the drug manufacturer Biogen (BIIB) continue to mount.
Among the many…
